Archemix Outlicenses Aptamers To Ophthotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.